회사 개요
Bio Green Med Solution, Inc. (BGMSP) is engaged in the distribution, trading, and installation of protective and fire safety materials, equipment, and systems, alongside the research and development of pharmaceuticals. The company operates within the healthcare sector, specifically in the biotechnology industry, which implies a focus on innovative medical solutions and safety technologies rather than traditional manufacturing. Regarding its operational scale, the firm reports a market capitalization of N/A and generates annual revenue of $747,000 based on trailing twelve-month figures. The employee count for the organization is listed as N/A, indicating limited public disclosure regarding headcount. These financial metrics suggest that the company functions as a micro-cap entity with minimal revenue generation relative to its sector peers, positioning it as a high-risk, early-stage biotechnology venture that relies heavily on R&D output and niche distribution contracts rather than established commercial dominance.
재무 건전성
The company's financial statements for the trailing twelve months reveal a revenue of $747,000 contrasted against a net income of $-14,092,000 and an EBITDA of $-8,422,000. The substantial gap between the nominal revenue and the negative net income highlights a severe cost structure where operating expenses and R&D expenditures vastly exceed current sales proceeds. Furthermore, the free cash flow stands at $-10,077,875, indicating that the company is consuming cash reserves to fund its operations and development pipeline rather than generating liquidity. The gross margin is recorded at -90.1%, while the operating margin reaches -162.5% and the profit margin is 0.0%, collectively signaling that the company is currently in a significant loss-making phase where costs are not covered by sales. In terms of liquidity, the firm holds $3.50M in cash against a negligible debt level of $2,000, resulting in a debt-to-equity ratio of 0.03. This balance sheet composition indicates a highly conservative leverage profile, as the company possesses substantial cash assets relative to its almost non-existent liabilities. The current ratio of 4.70 suggests strong short-term liquidity, meaning the company has ample current assets to cover its short-term obligations. However, the return on equity is -128.4% and the return on assets is -85.8%, revealing that management has not yet achieved profitability and is currently eroding shareholder value and asset efficiency through accumulated losses.
밸류에이션 평가
The trailing P/E ratio is N/A and the forward P/E is also N/A due to the company's negative earnings, which precludes the use of standard earnings-based valuation multiples. The price-to-book ratio is 0.67, indicating that the market values the company at approximately 67% of its book value, suggesting the market prices in significant future risks or expects a turnaround from the current losses. The price-to-sales ratio is N/A, and the EV/EBITDA stands at -0.14, reflecting a valuation that is heavily dependent on asset backing rather than earnings power or sales multiples. The stock has experienced extreme volatility over the past year, trading between a 52-week high of $14.00 and a 52-week low of $0.30. Without a specific current price provided in the available facts to calculate the exact percentage deviation, the range demonstrates the stock's sensitivity to market sentiment regarding its biotechnology pipeline and cash burn rate. The beta value of -0.53 is highly unusual for equities, implying an inverse correlation with the broader market where the stock tends to move in the opposite direction of the market index. This negative beta suggests that the stock's price movements are driven by specific idiosyncratic factors related to the biotechnology sector or the company's unique operational risks rather than general market trends.
Growth & Income
The revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, preventing a direct comparison of earnings growth speed relative to revenue expansion. Because the company reports a net income of $-14,092,000 and a profit margin of 0.0%, it is not a dividend payer and consequently does not distribute any cash returns to shareholders. The dividend yield is reported as 70.6%, yet the payout ratio is N/A, which creates a complex metric that must be interpreted with caution given the negative earnings base that typically precludes sustainable dividend payouts. Instead of paying dividends, the company reinvests its limited cash flow, currently $-10,077,875, into research, development, and operational expenses to attempt to achieve future profitability. The overall growth and income profile is characterized by a lack of historical earnings growth data, a complete absence of sustainable dividends due to negative net income, and a valuation strategy focused on potential future asset realization rather than current income generation.